Overview of the disease burden of invasive pneumococcal disease in Asia

Bravo, Lulu

doi:10.1016/j.vaccine.2009.04.046

Cited by 69 publications

(51 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 The high morbidity and mortality in infants and elderly in both countries thus are translated into high economic burden in terms of cost of management of complications. 5 A 7-valent pneumococcal conjugate vaccine (PCV7; Prevenar) was approved for pediatric use and recommended by Advisory Committee on Immunization Practices (ACIP) of the US for children aged up to 59 months in 2000, and use expanded around the world in the years that followed. 6 Routine use of PCV7 in children <5 years has markedly decreased the incidence of IPD, pneumonia, and otitis media due to vaccine serotype pneumococcus in several countries where it has been used.…”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong

Roberts

Lee

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Keywords: herd effect, incremental cost-effectiveness ratio (ICER), Markov transition-state model, pneumococcal disease, 13-valent pneumococcal conjugate vaccine (PCV13), 10-valent pneumococcal conjugate vaccine (PCV10)Pneumococcal disease causes large morbidity, mortality and health care utilization and medical and non-medical costs, which can all be reduced by effective infant universal routine immunization programs with pneumococcal conjugate vaccines (PCV). We evaluated the clinical and economic benefits of such programs with either 10-or 13-valent PCVs in Malaysia and Hong Kong by using an age-stratified Markov cohort model with many country-specific inputs. The incremental cost per quality-adjusted life year (QALY) was calculated to compare PCV10 or PCV13 against no vaccination and PCV13 against PCV10 over a 10-year birth cohort's vaccination. Both payer and societal perspectives were used. PCV13 had better public health and economic outcomes than a PCV10 program across all scenarios considered. For example, in the base case scenario in Malaysia, PCV13 would reduce more cases of IPD (C2,296), pneumonia (C705,281), and acute otitis media (C376,967) and save more lives (C6,122) than PCV10. Similarly, in Hong Kong, PCV13 would reduce more cases of IPD cases (C529), pneumonia (C172,185), and acute otitis media (C37,727) and save more lives (C2,688) than PCV10. During the same time horizon, PCV13 would gain over 74,000 and 21,600 additional QALYs than PCV10 in Malaysia and Hong Kong, respectively. PCV13 would be cost saving when compared against similar program with PCV10, under both payer and societal perspective in both countries. PCV13 remained a better choice over PCV10 in multiple sensitivity, scenario, and probabilistic analyses. PCV13s broader serotype coverage in its formulation and herd effect compared against PCV10 were important drivers of differences in outcomes.

show abstract

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong

Roberts

Lee

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…1,4,5 Recent studies were conducted in Indonesia, as many as 67.8% Streptococcus pneumoniae in nasopharyngeal specimens in children aged 2-5 years old with pneumonia. 6 Death due to pneumonia which is caused by Streptococcus pneumoniae and Haemophillus influenzae are 32.7% and 15.7% respectively. 4 Resistance to antibiotics is one of the causes of high mortality rate.…”

Section: Introductionmentioning

confidence: 99%

“…6 A study conducted in Pakistan 9 among children aged 2-59 months with clinical symptoms of pneumonia such as lower chest indrawing and rapid breathing that had treatment failure of intravenous ampicillin was 5.8% on third day and 8.6% on sixth day of therapy.…”

Section: Introductionmentioning

confidence: 99%

Treatment Failure of Ampicillin to Children with Pneumonia at Dr. Hasan Sadikin General Hospital Bandung from 2014–2015

Suharno¹,

Husen²,

Sudarwati³

2017

amj

View full text Add to dashboard Cite

Background: Pneumonia is one of the causes of death in infants in developing countries especially Indonesia. Appropriate treatment is needed to decrease mortality rate in children due to pneumonia. Ampicillin is one of first choices empirical antibiotic to children with severe pneumonia. The study was aimed to determine the failure rate of ampicillin in children with severe pneumonia. Methods: This study was a descriptive study which used medical records as source of data. Subjects were children aged 2-59 months with World Health Organization (WHO) defined with severe pneumonia and treated with intravenous ampicillin during January 2014 to July 2015 at Dr. Hasan Sadikin General Hospital Bandung. Samples were obtained using total sampling method while variables were analyzed using statistics software. Results: This study acquired 107 patients who met the inclusion criteria with 23.36% of them aged 2-11 months and 62.21% aged 12-23 months. Majority of subjects were male amounted as 63.55% while female occupied 36.45%. Treatment failure on the third day was 45.8% while 16.7% on the sixth day of therapy with majority failure due to existence of lower chest indrawing. Conclusions: Treatment failure on the third and sixth day of therapy still high that is characterized by the existence of lower chest indrawing as its main factor. [AMJ.2017;4(1):100-6]

show abstract

“…Pneumococcal disease causes a large number of deaths every year. According to the estimate of World Health Organization (WHO) that 1.6 million die every year from the invasive disease, 0.7-1 million of which are children aged < 5 years (Bravo, 2009). Because the use of antibiotics is more and more extensive, there is more bacterium strains resistance to multiple antibiotics.…”

Section: Introductionmentioning

confidence: 99%

Research progress of Streptococcus pneumoniae capsular polysaccharide-protein conjugate vaccines

Long¹,

Hou²,

Feng³

et al. 2012

Afr. J. Microbiol. Res.

View full text Add to dashboard Cite

Streptococcus pneumoniae is a major respiratory pathogen responsible for many diseases in young children and elderly. Because of the increasing antibiotic resistance of pneumococci recently, the need for development of an effective vaccine is more and more urgent. Since the 7-valent conjugate vaccine was licensed in the United States in 2000, its efficacy has been widely recognized. Effort on researching polysaccharide-protein conjugate vaccine never stopped. This article reviewed the conjugate vaccines in view of the carrier proteins.

show abstract

Overview of the disease burden of invasive pneumococcal disease in Asia

Cited by 69 publications

References 34 publications

Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong

Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong

Treatment Failure of Ampicillin to Children with Pneumonia at Dr. Hasan Sadikin General Hospital Bandung from 2014–2015

Research progress of Streptococcus pneumoniae capsular polysaccharide-protein conjugate vaccines

Contact Info

Product

Resources

About